Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.71 +4.2%	$2.67	$1.20 ▼ $6.75	$148.03M	2.87	888,161 shs	811,932 shs
RLAY Relay Therapeutics	$3.41 +0.3%	$3.49	$1.77 ▼ $10.72	$586.20M	1.62	2.55 million shs	1.02 million shs
TERN Terns Pharmaceuticals	$6.76 +7.3%	$5.16	$1.87 ▼ $11.40	$551.32M	-0.05	1.14 million shs	1.12 million shs
VIR Vir Biotechnology	$4.38 +0.5%	$5.16	$4.16 ▼ $14.45	$605.68M	1.18	1.03 million shs	829,630 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	-1.89%	-6.14%	-17.46%	+26.21%	-54.78%
RLAY Relay Therapeutics	0.00%	-0.58%	-6.34%	+19.30%	-53.10%
TERN Terns Pharmaceuticals	-3.82%	-2.93%	+11.70%	+114.29%	-16.11%
VIR Vir Biotechnology	0.00%	-4.60%	-21.01%	-5.42%	-50.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.3338 of 5 stars	3.6	1.0	0.0	3.9	1.7	1.9
RLAY Relay Therapeutics	2.0166 of 5 stars	3.5	0.0	0.0	2.1	2.5	0.6
TERN Terns Pharmaceuticals	3.7352 of 5 stars	3.3	1.0	4.1	1.9	3.3	0.0
VIR Vir Biotechnology	3.3644 of 5 stars	3.4	2.0	0.0	3.0	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.17	Buy	$12.40	357.56% Upside
RLAY Relay Therapeutics	2.92	Moderate Buy	$17.25	405.87% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	131.14% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	590.64% Upside

Current Analyst Ratings Breakdown

Latest BDTX, VIR, TERN, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	BDTX Black Diamond Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/8/2025	RLAY Relay Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $19.00
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
RLAY Relay Therapeutics	$10.01M	58.73	N/A	N/A	$3.86 per share	0.88
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$3.49 per share	N/A
VIR Vir Biotechnology	$74.21M	8.20	N/A	N/A	$6.82 per share	0.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$69.68M	$0.23	11.30	N/A	N/A	N/A	12.70%	9.58%	11/4/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$1.95	0.00	N/A	N/A	N/A	-41.49%	-37.43%	11/5/2025 (Estimated)
TERN Terns Pharmaceuticals	-$88.85M	-$1.04	0.00	N/A	N/A	N/A	-27.35%	-26.18%	N/A
VIR Vir Biotechnology	-$521.96M	-$4.00	0.00	N/A	N/A	-2,895.94%	-50.22%	-40.78%	10/30/2025 (Estimated)

Latest BDTX, VIR, TERN, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BDTX Black Diamond Therapeutics	-$0.25	-$0.19	+$0.06	-$0.19	N/A	N/A
8/7/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	-$0.41	+$0.08	-$0.41	$0.07 million	$0.70 million
8/6/2025	Q2 2025	VIR Vir Biotechnology	-$0.72	-$0.80	-$0.08	-$0.80	$2.38 million	$1.21 million
8/5/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	8.73	8.73
RLAY Relay Therapeutics	N/A	20.92	20.92
TERN Terns Pharmaceuticals	N/A	24.70	24.70
VIR Vir Biotechnology	N/A	7.01	7.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
RLAY Relay Therapeutics	96.98%
TERN Terns Pharmaceuticals	98.26%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
RLAY Relay Therapeutics	4.87%
TERN Terns Pharmaceuticals	1.50%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.94 million	53.54 million	Optionable
RLAY Relay Therapeutics	330	172.41 million	164.02 million	Optionable
TERN Terns Pharmaceuticals	40	87.51 million	86.20 million	Not Optionable
VIR Vir Biotechnology	580	138.92 million	116.69 million	Optionable

BDTX, VIR, TERN, and RLAY Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Tejara Capital Ltd

August 17, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for VIR Earnings

August 12, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Outlook for VIR Earnings

August 12, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month Low - Here's Why

August 10, 2025 | marketbeat.com

Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)

August 9, 2025 | theglobeandmail.com

Vir Biotechnology (NASDAQ:VIR) Trading Down 11.1% Following Weak Earnings

August 8, 2025 | marketbeat.com

Vir Biotechnology Reports Q2 2025 Financial Results

August 7, 2025 | msn.com

Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum

August 7, 2025 | msn.com

Vir (VIR) Q2 Revenue Drops 61%

August 7, 2025 | fool.com

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 6, 2025 | businesswire.com

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

August 6, 2025 | businesswire.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $109,780.00 in Stock

August 5, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from Brokerages

August 1, 2025 | marketbeat.com

Vir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical Setbacks

July 31, 2025 | genengnews.comG

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31, 2025 | businesswire.com

Allianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

July 30, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BDTX, VIR, TERN, and RLAY Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.71 +0.11 (+4.23%)

Closing price 04:00 PM Eastern

Extended Trading

$2.70 0.00 (-0.18%)

As of 07:15 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics NASDAQ:RLAY

$3.41 +0.01 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$3.42 +0.00 (+0.15%)

As of 07:31 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Terns Pharmaceuticals NASDAQ:TERN

$6.76 +0.46 (+7.30%)

Closing price 04:00 PM Eastern

Extended Trading

$6.77 +0.01 (+0.15%)

As of 07:25 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Vir Biotechnology NASDAQ:VIR

$4.38 +0.02 (+0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$4.41 +0.03 (+0.66%)

As of 07:56 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time